Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
130,300
+3,700 (2.92%)
At close: Feb 27, 2026
284.37%
Market Cap 2.77T
Revenue (ttm) 25.48M
Net Income (ttm) -36.88B
Shares Out 21.23M
EPS (ttm) -2,048.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 632,243
Average Volume 332,485
Open 124,600
Previous Close 126,600
Day's Range 123,900 - 132,800
52-Week Range 15,950 - 146,600
Beta n/a
RSI 58.77
Earnings Date Mar 20, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.